EVENTS

The Biological Safety Centre BioSC will take part in the “Italia degli Innovatori 2011/2012” project, an initiative promoted by the Italian Government to showcase an Italy that can do innovation and our country’s excellent technological achievements.  BioSC, a centre specialising in viral validation studies which has been working at the Kedrion’s plant in Bolognana (Lucca

Kedrion, a biopharmaceutical company specialising in the development, manufacture and distribution of plasma-derived products, is one of the major participants in the fifth edition of Forum on Health Risk Management taking place in Arezzo (Italy) until November 26th. In particular, Kedrion took part in the meeting of November 23rd called “Safety of blood-derived products”, chaired

Kedrion has won the institutional Haemophilia Federation India (HFI) award. As part of the celebrations for the 25th anniversary of the foundation of HFI, in New Delhi, India’s Health and Welfare Minister Ambumani Ramadoss gave Kedrion’s Piersergio Martini an award for the company’s long-term support to the mission of increasing the availability of coagulation factors, i.e.

 The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307, Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated

As part of the XXXVIII National Conference on Transfusion Medicine, the Scientific Committee of SIMTI (Italian Society of Transfusion and Immunohaematologic Medicine) has selected, as the winner for the session “transfusion-transmitted diseases”, the presentation Viral Risk Assessment – Modello Kedrion: applicazione nell’ambito del plasma italiano destinato alla lavorazione industriale (Viral Risk Assessment – Kedrion’s model:

The Minister of Reform and Innovation in the Public Administration, Luigi Nicolais, recently visited the Kedrion plant for the production of plasma-derived products in Sant’Antimo, near Naples. Kedrion Group, specialising in the production and distribution of pharmaceutical products derived from plasma proteins, has a total of three production plants: in addition to the one in

Kedrion (Italy) is the only company working in the plasma derivatives industry which is sitting on the organising committee of the EMEA/PDA (Parenteral Drug Association) Joint Conference. The company appointed Claudia Nardini, in charge of Industrial Development and Research for the company and deputy president of the Italian chapter of the PDA, as its delegate;